Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 539-550

  Talakad, Jyothi C ^a   Shah, Manish B ^a   Walker, Gregory S ^c   Xiang, Cathie ^b   Halpert, James R ^a   Dalvie, Deepak ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOTICLOPIDINE; 5 (2 CHLOROBENZYL)THIENO[3,2 C]PYRIDIN 5 IUM METABOLITE; 7 HYDROXYTICLOPIDINE; CYTOCHROME P450 2B4; CYTOCHROME P450 2B6; DRUG METABOLITE; THIOPHENE; TICLOPIDINE; TICLOPIDINE N OXIDE; TICLOPIDINE S OXIDE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; DIMERIZATION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PLATELET AGGREGATION INHIBITORS; RABBITS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

KOBUS; ORYCTOLAGUS CUNICULUS;

EID: 79951873368     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037101     Document Type: Article

References (40)

1. Beck ME (2005) Do Fukui function maxima relate to sites of metabolism? A critical case study. J Chem Inf Model 45:273-282.
2. Dalvie DK and O'Connell TN (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab Dispos 32:49-57. (Pubitemid 38112535)
3. Dansette PM, Libraire J, Bertho G, and Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 22:369-373.
4. Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126-142.
5. Gay SC, Roberts AG, Maekawa K, Talakad JC, Hong WX, Zhang Q, Stout CD, and Halpert JR (2010b) Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel. Biochemistry 49:8709-8720.
6. Gay SC, Roberts AG, and Halpert JR (2010c) Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by x-ray crystallography and NMR. Future Med Chem 2:1451-1468.
7. Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, et al. (2010a) Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl) imidazole at 2.0-A resolution. Mol Pharmacol 77:529-538.
8. Gay SC, Sun L, Maekawa K, Halpert JR, and Stout CD (2009) Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning. Biochemistry 48:4762-4771.
9. Grieco A, Vecchio FM, Greco AV, and Gasbarrini G (1998) Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 10:713-715. (Pubitemid 28383121)
10. Guengrich FP (2005) Human cytochrome P450 enzymes, in Cytochromes P450: Structure, Mechanism and Biochemistry, 3rd ed (Ortiz de Montellano PR ed), pp 377-350, Plenum Press, New York.
11. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, and Mansuy D (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122. (Pubitemid 32946552)
12. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402. (Pubitemid 27102356)
13. Johnson EF and Stout CD (2005) Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336. (Pubitemid 41540575)
14. Kam PC and Nethery CM (2003) The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58:28-35. (Pubitemid 36113325)
15. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506. (Pubitemid 34171915)
16. Ko JW, Desta Z, Soukhova NV, Tracy T, and Flockhart DA (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Brit J Clin Pharmacol 49:343-351. (Pubitemid 30195277)
17. Kumar S, Chen CS, Waxman DJ, and Halpert JR (2005) Directed evolution of mammalian cytochrome P4502 B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem 280:19569-19575. (Pubitemid 41379478)
18. Kumar S, Zhao Y, Sun L, Negi SS, Halpert JR, and Muralidhara BK (2007) Rational engineering of human cytochrome P450 2B6 for enhanced expression and stability: importance of a Leu264->Phe substitution. Mol Pharmacol 72:1191-1199. (Pubitemid 350012593)
19. Lewis DF and Ito Y (2008) Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin Drug Metab Toxicol 4:1181-1186.
20. Mataix R, Ojeda E, Perez MC, and Jimenez S (1992) Ticlopidine and severe aplastic anaemia. Br J Haematol 80:125-126.
21. Mitsuda M and Iwasaki M (2006) Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in Escherichia coli. Protein Expr Purif 46:401-405.
22. Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, and Ikeda T (2009) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 37:589-593.
23. Oliver CF, Modi S, Primrose WU, Lian LY, and Roberts GC (1997) Engineering the substrate specificity of Bacillus megaterium cytochrome P-450 BM3: hydroxylation of alkyl trimethylammonium compounds. Biochem J 327:537-544. (Pubitemid 27477834)
24. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
25. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, and Yamaguchi M (1991) Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 37:239-242.
26. Onyeji CO, Tessier PR, Nightingale CH, Vallee F, and Nicolau DP (1999) Pharmacokinetics of ticlopidine in the rabbit. J Pharm Pharmacol 51:393-396. (Pubitemid 29248314)
27. Panak E, Maffrand JP, Picard-Fraire C, Vallee E, Blanchard J, and Roncucci R (1983) Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 13 (Suppl 1):1-54.
28. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197. (Pubitemid 38090717)
29. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
30. Scott EE, White MA, He YA, Johnson EF, Stout CD, and Halpert JR (2004) Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 279:27294-27301. (Pubitemid 38812569)
31. Sharis PJ, Cannon CP, and Loscalzo J (1998) The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 129:394-405. (Pubitemid 28402795)
32. Shimizu S, Atsumi R, Nakazawa T, Fujimaki Y, Sudo K, and Okazaki O (2009) Metabolism of ticlopidine in rats: identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide. Drug Metab Dispos 37:1904-1915.
33. Steinhubl SR, Tan WA, Foody JM, and Topol EJ (1999) Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA 281:806-810. (Pubitemid 29113740)
34. Strickler M, Goldstein BM, Maxfield K, Shireman L, Kim G, Matteson DS, and Jones JP (2003) Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101). Biochemistry 42:11943-11950. (Pubitemid 37280644)
35. Talakad JC, Wilderman PR, Davydov DR, Kumar S, and Halpert JR (2010) Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: insights into structural importance of residue 334. Arch Biochem Biophys 494:151-158.
36. Tuong A, Bouyssou A, Paret J, and Cuong TG (1981) Metabolism of ticlopidine in rats: Identification and quantitative determination of some its metabolites in plasma, urine and bile. Eur J Drug Metab Pharmacokinet 6:91-98. (Pubitemid 11032654)
37. Walsky RL, Astuccio AV, and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426-1438. (Pubitemid 44704203)
38. Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-1018.
39. Zhao Y, Sun L, Muralidhara BK, Kumar S, White MA, Stout CD, and Halpert JR (2007) Structural and thermodynamic consequences of 1-(4-chlorophenyl) imidazole binding to cytochrome P450 2B4. Biochemistry 46:11559-11567. (Pubitemid 47585501)
40. Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, and Stout CD (2006) Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem 281:5973-5981. (Pubitemid 43847698)